The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer–BioNTech) led to a resurgence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback